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TUMOR-INDUCED IMMUNE EVASION OF CD8+ T CELLS
Abstract
The concept of tumor immune evasion is a prevalent obstacle in cancer research and the
development of immunotherapies. Increased insight into mechanisms that are responsible for the
escape of cancer cells from the immune system will help to improve therapeutic approaches and
provide understanding into slowing disease progression by utilizing the body’s immune system.
With immunotherapy development on the forefront of cancer research due to seemingly
attenuated toxicity and resistance when compared to traditional chemoradiotherapy, analyzing
these obstacles is essential for emerging roles and future directions in the discipline of
immuno-oncology. Understanding the immunosuppressive molecules that contribute to the
process of tumor-induced immune evasion, as well as the immunomodulatory molecules that
may help bypass these barriers in cancer treatment, will help to provide insight into new
therapeutic development and increase efficacy of existing treatments. A subtype of
T-lymphocyte, CD8+ cytotoxic T cells, are key players in viral infections and in the tumor
microenvironment, so when their effector functions are limited or inhibited, the body becomes
less capable of fighting the cancer and more susceptible to disease progression and metastasis.
Insight into how these mechanisms impact the activity within the tumor microenvironment is
pertinent in the ongoing battle to develop novel, efficacious cancer treatments. In this review, a
few key pathways that contribute to immune evasion and suppression of these CD8+ T cells will
be discussed, as well as immunotherapies that are focused on combating the obstacles that these
mechanisms introduce.
Introduction
Typically, the key players in the immune system are able to recognize foreign and potentially
harmful antigens, initiate inflammatory responses, induce phagocytosis of possibly infected cells,
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and develop adaptive responses in order to acquire memory against invaders. Adaptive responses
involve antigen-specific immune cells and the subset that will be focused on in this review are
known as CD8+ cytotoxic T lymphocytes. This subset is primarily responsible for detection and
destruction of virally infected cells and cancer cells by recognizing foreign antigens presented on
MHC I proteins, which are present on all nucleated cells. CD8+ T cells then secrete
antimicrobial cytokines as well as cytotoxic granules, which are released into the targeted cell
and shut down production of viral proteins while also inducing apoptosis, or programmed cell
death. Due to the fact that cancer cells typically have foreign antigens presented on their
surfaces, these mechanisms of action should allow CD8+ T cells to disrupt progression of
disease. However, cancer cells utilize a wide variety of mechanisms at the microenvironmental
level that result in tumor immune evasion. Tumor immune evasion refers to the phenomenon in
which cancer can continue to progress and metastasize by avoiding the immune system’s
mechanisms of recognition and attack. Tumor-induced immunosuppression has various
mechanisms, most of which revolve around the recruitment and activation of immunosuppressive
cells in the tumor microenvironment which secrete factors that contribute to immune system
evasion. Another mechanism of tumor-induced immunosuppression involves the expression of
immunosuppressive molecules and receptors on the surface of tumor cells. These are known as
immune checkpoints and their overexpression, commonly characterized by cancer cells, can lead
to the inhibition of immune responses and therefore contribute to the progression of disease and
resistance to treatment. Checkpoint blockade therapy has revolutionized the field of
immuno-oncology as one of the most prominent and up-and-coming immunotherapies. These
drugs are designed to interfere with inhibitory pathways that restrict immune responses against
cancer cells, thus combating this tumor immune evasion and provoking a response. This review
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will focus on a few key mechanisms that contribute to the suppression of CD8+ T cell effector
functions in the tumor microenvironment, serving as a barrier to immune responses and cancer
therapies.
Myeloid-derived suppressor cells
The myeloid lineage of immune cells plays a critical role in responses against infection,
promoting inflammation, and linking the adaptive and innate immune responses. Fully
differentiated cells of this lineage include dendritic cells, monocytes, mast cells, and
granulocytes. A subset of these called myeloid derived suppressor cells are myeloid progenitors
that have never fully differentiated into one of the previously mentioned cell types (Gabrilovich
et. al., 2017). They are typically found in bone marrow, peripheral blood, spleen, liver, lungs, and
certain tumor types (Gabrilovich et. al., 2017). Myeloid derived suppressor cells are thought to
play a role in processes such as chronic inflammation, infection, autoimmune diseases, trauma,
graft versus host disease, and are now a prevalent area of interest in tumor immunology
(Gabrilovich et. al., 2017). MDSCs have been shown to contribute to immunosuppression
significantly, with their main target being T cells. Tumor and host cells in the tumor
microenvironment produce several pro-inflammatory molecules that activate and recruit MDSCs
to the tumor microenvironment, driving their suppressive activity. MDSCs have been isolated
from human cancer patients who exhibit high levels of these cells, and these high levels have
shown correlation with clinical cancer staging and metastatic burden of disease (Law et al., 2020.
Specific cancer types that frequently are associated with high levels of MDSCs include
non-small cell lung cancer, multiple myeloma, non-Hodgkin's lymphoma, renal cell carcinoma,
esophageal cancer, sarcomas, breast cancers, pancreatic adenocarcinoma, and colorectal cancer
(Damuzzo et. al., 2014). The transcription factors in the STAT family, such as STAT1, STAT3,
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STAT6, and NFκB, are significant regulators of MDSC recruitment and activation. Cancer cells
and tumor-associated stromal cells play roles in activating these pathways (Law et al., 2020).
Previous findings have shown a significant correlation between chronic inflammation and
malignant growth, as well as the concept of inflammation-induced MDSC recruitment and
activity. Interleukin-1β (IL-1β) is another key player in MDSC activity, as well as in the
suppression of CD8+ T cell function. It is a pro-inflammatory cytokine that is secreted by many
tumor types and other cells in the tumor microenvironment. Tumor-derived IL-1β secreted into
the tumor microenvironment has been shown to induce the accumulation of MDSC possessing
an enhanced capacity to suppress T cells (Elkabets et. al., 2010). The IL-1 pathway in CD8+ T
cells is far from being fully understood, but it has been shown that IL-1R-/- CD8+ effector cells
contain transcripts for perforin and granzyme, but only express perforin (Joeckel et al., 2012).
Lack of granzyme results in inhibition of in vitro apoptosis by CD8+ T cells unless exogenous
granzyme is present. Overall results of this study showed significant reduction in expansion of
antigen-specific CD8+ T cells, leading to the conclusion that the IL-1/IL-1R pathway is crucial
for full maturation of functionally competent CD8+ T cells (Joeckel et al., 2012). When the
IL-1β pathway was perturbed in mice with 4T1 mammary carcinoma tumors by removing the
IL-1β receptor, IL-1R, the extent of inflammation was manipulated. A delay in MDSC
accumulation was observed, along with slowed tumor progression (Bunt et al., 2007).
Essentially, when tumor cells and other cells of the tumor microenvironment secrete IL-1, it
contributes to the recruitment and activation of these myeloid derived suppressor cells, which
further the immunosuppressive activity that is seen as an obstacle for many cancer therapies. It
was also hypothesized that IL-6, another pro-inflammatory mediator, is a downstream regulator
of IL-1β’s inflammatory and tumor-promoting functions, and that transfecting these same mice
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with the human IL-6 gene should compensate for the loss of IL-1R (Bunt et al., 2007). No delay
in progression of 4T1/IL-6 tumors was observed in IL-1R-/- mice with the transfected IL-6 gene,
and they seemed to progress at a similar rate as 4T1/IL-6 tumors in the traditional mouse model
(Bunt et al., 2007). Because of the link between IL-1 and IL-6 in primary tumor site activity, the
metastatic activity of these tumors was also analyzed. Metastatic disease progression to the lungs
also progressed in a similar fashion, proposing the idea that IL-6 also serves as a downstream
mediator of IL-1 in metastatic mechanisms and that IL-6 does in fact compensate for the loss of
IL-1R in disease-progressive mechanisms. To summarize these findings, IL-1 induced MDSC
recruitment can lead to immunosuppressive activity in the tumor microenvironment as well as
depletion of the population of functional CD8+ T cells. On another hand, LCK is a protein
associated with the cytoplasmic tails of the co-receptors of CD4+ and CD8+ T cells and has been
shown to aid in signaling and activation of these T cells (Feng, et al., 2018). MDSCs have been
shown to be involved in the nitration of LCK, impairing activation and signaling pathways and
contributing to CD8+ T cell-specific immunosuppression. LCK nitration has also shown reduced
levels of IL-2 in the tumor microenvironment (Feng, et al., 2018). IL-2 is a common target for
immunotherapies as it is strongly correlated with T cell differentiation and proliferation,
acquisition of effector functions, and cytotoxic activity. Recombinant IL-2 therapy shows partial
and complete regression of disease alone, and has been utilized as a combination therapy
alongside other cancer treatments, showing positive clinical outcomes (Choudry, et al., 2018).
Therefore, the inhibitory effects of MDSCs on IL-2 would hinder the regression of disease and
limit the therapeutic potential of the cytokine. Another signaling cascade that is modified by the
presence of MDSCs involves TCR-CD3 signaling. CD3 is a T cell co-receptor that is involved in
activating both the CD4+ and CD8+ subsets of T cells. It is believed that the integrity of the
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TCR-CD3 complex is altered by MDSCs, as well as the physical interaction between TCR and
CD8+ (Nagaraj, et al., 2010). The obstruction of these signaling pathways prevents the immune
system from generating tumor antigen-specific CD8+ T cells and serves as a significant
mechanism of tolerance in systemic CD8+ T cells as well as the CD8+ T cell population of the
tumor microenvironment (Nagaraj, et al., 2010). A promising area of immunotherapeutic
research revolves around the induction of MDSC differentiation. All-trans-retinoic-acid (ATRA)
has been utilized to inhibit retinoic signaling to promote differentiation and shift MDSCs into
mature myeloid cells, such as macrophages and dendritic cells. ATRA has resulted in the
attenuation of T cell suppression and mice and patient models of multiple types of cancers have
exhibited reduced levels of circulating MDSCs, enhanced response to cancer vaccine treatments,
improved dendritic cell function, and enhanced antigen-specific T cell response (Law, et al.,
2020). Another potential treatment discussed in this study was the utilization of MDSC depletion
combined with other immunotherapies. Checkpoint inhibitors anti-PD1 and anti-CTLA4
combined with epigenetic modulatory drugs, which have been used to functionally inhibit
MDSCs, resulted in complete tumor regression and metastatic progression of TNBC cancer cell
line 4T1 with over an 80% survival rate 100 days post-tumor implantation (Law, et al., 2020).
When the two epigenetic modulatory drugs used in that study, entinostat and 5-azacytidine, were
used together but not in combination with the checkpoint inhibitors, the primary and metastatic
progression remained, leading to the hypothesis of the synergistic effects of combining
checkpoint inhibitors and MDSC-targeted therapy. There are some complexities and challenges
in targeting MDSC populations in cancer therapy. One of the most prevalent obstacles is the
heterogeneity of MDSC composition. MDSCs have shown that they lack the markers associated
with mature myeloid cells, so identifying the presence and overall impact of MDSCs in a cancer
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patient has been difficult to execute (Damuzzo, et al., 2014). Research focused around
identifying further markers and morphological characteristics of MDSCs in human and murine
models is underway, which will provide more insight into utilizing the tendencies and pathways
that we are aware of in these immunosuppressive cells for immunotherapeutic development.
The PD-1/PD-L1 pathway
The PD-1/PD-L1 pathway plays a crucial role in the promotion of self-tolerance and the
inhibition of immune responses in the tumor microenvironment by attenuating and manipulating
T cell activity, inhibiting apoptosis of regulatory T cells, and inducing apoptosis of
antigen-specific T cells (Han et. al., 2020). PD-1 is a receptor on the surface of activated T cells,
NK cells, B cells, macrophages, dendritic cells, and monocytes, while PD-L1, programmed death
ligand 1, is its ligand that is present on antigen presenting cells, such as dendritic cells and
macrophages, some activated T cells and B cells, and some epithelial cells under inflammatory
conditions. Typically, PD-L1 is utilized as a co-inhibitory factor in this pathway to inhibit
immune responses and self-tolerance to ensure that the immune system is only activated at
appropriate times to minimize chronic inflammation and autoimmune responses (Qin et. al.,
2019). The molecule serves a dual role as being beneficial and detrimental. It is beneficial in the
way that its promotion of self-tolerance and inhibition of responses helps to downplay
recognition of self, therefore limiting autoimmune responses. However, this pathway is largely
responsible for cancer immune escape and resistance mechanisms to adaptive immune responses
and cancer treatments. Certain proinflammatory cytokines present in the tumor
microenvironment such as IFN-γ, IL-6, and TNF-α are responsible for the upregulation of
expression of PD-L1 on tumor cells (Chan et al., 2019). This phenomenon results in attenuation
of immune responses and progression of disease. Amplification and translocations present in the
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genomic region of PD-L1 have been shown to lead to upregulation of PD-L1. These genomic
rearrangements have been shown to play a role in tumor immune evasion in cancers such as
primary mediastinal large B cell lymphoma (PMBCL), NSCLC, squamous cell carcinoma, and
gastric adenocarcinoma (Green, et. al., 2010). While certain mechanisms have been studied that
specifically impair the function of CD8+ T cells, there has also been a correlation seen between
the inhibition of cytotoxic T cell activity and the amplification of immune-inhibitory cell types.
In a study looking at PD-L1 expressing CD8+ T cells in melanoma patients, it was shown that an
increase in PD-L1+ CD8+ T cells correlates with markers indicative of a negative immune
climate. These markers include a decrease in plasmacytoid dendritic cells, an increase in myeloid
derived suppressor cells, and a strong correlation with the presence of regulatory T cells
(Brochez, et. al., 2018). This study also demonstrated an increase in PD-L1+ CD8+ T cells in
patients who relapsed and/or died from melanoma, leading to the conclusion that increased
PD-L1 expression on these lymphocytes is correlated with poor prognoses. An interesting
mechanism of metastatic progression in many cancer cell lines is epithelial-mesenchymal
transition (EMT). EMT enables carcinoma cells to suppress their epithelial features and begin
expressing mesenchymal ones. This phenomenon gives tumor cells the ability to acquire
mobility and migrate from the primary site of the tumor, resulting in disease progression and
metastasis (Ramos et. al., 2017). The presence of EMT in cancer has been strongly associated
with the exhaustion of CD8+ T cells in the tumor microenvironment (Romeo et. al., 2019), but
also has been shown to be positively associated with PD-L1 levels (Chen et. al., 2017). In a study
analyzing the role of PD-L1 in molecular pathways, specifically EMT, in a human esophageal
cell line, it was found that tumors in the EMT positive subgroup also exhibited higher levels of
PD-L1 expression than tumor samples in the EMT negative subgroup (Chen et. al., 2017). In this
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same study, it was found that manipulating the cell lines to overexpress PD-L1 resulted in a
significant promotion of cell viability, migration, and EMT phenotype compared to cell lines
with ablation of PD-L1. These findings exhibit the correlation between PD-L1 overexpression
and epithelial-mesenchymal transition, which is a significant contributing factor to disease
progression and metastasis, while CD8+ T cell populations are exhausted and dysfunctional. It
has been suggested that therapeutic approaches designed to reverse EMT induced
immunosuppression may provide synergistic therapeutic effects combined with PD-L1 blockade
(Jiang et. al., 2020). Alongside the PD-1/PD-L1-dependent indirect mechanisms in which T cell
populations are attenuated and functions are suppressed in the tumor microenvironment, there is
also data surrounding the direct effect of PD-L1 expression on CD8+ T cells. PD-L1 is
upregulated on T cells in the tumor microenvironment following antigen presentation and as a
response to inflammatory conditions (Diskin, et. al., 2020). Findings in this study indicate the
suppression of neighboring T cells in the tumor microenvironment in the presence of PD-L1+ T
cells, suggesting that the upregulation of PD-L1 on T cells maintains intra-tumoral immune
tolerance via both innate and adaptive mechanisms. It was found that Pdl1-/- T cells were
permissive of cytotoxic T cell activation, while Pdl1+/+T cells had an inhibitory effect on
cytotoxic T cell activation. To summarize, the expression of PD-L1 on T cells in the tumor
microenvironment directly correlates with suppressive activity of CD8+ T cells in the tumor
microenvironment, and the depletion of functional CD8+ T cells is observed secondary to
disease progression stimulated by PD-L1 expression on other cell types. While there are
significant obstacles presented by PD-L1 overexpression in the tumor microenvironment, the
PD-1/PD-L1 pathway is a promising and progressive area of immunotherapeutic research. An
approach that is frequently utilized is known as checkpoint blockade therapy, where anti-PD-1
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antibodies are administered which bind to PD-1. This prevents PD-1/PD-L1 interaction,
therefore inhibiting the immunosuppressive activity that is seen when the two bind (Martin-Ruiz,
et. al., 2020). This approach has been widely tested and has shown significant, and very
promising, effects on disease progression, recurrence, and patient survival in those with PD-L1
positive tumors. To date, five PD-1/PD-L1 targeted immunotherapies have been approved by the
Food and Drug Administration, two anti-PD-1 antibodies, nivolumab and pembrolizumab, and
three anti-PD-L1 antibodies, avelumab, atezolizumab, and durvalumab (Qin et. al., 2019).
Nivolumab has been approved for the treatment of non-small cell lung cancer (NSCLC), renal
cell carcinoma (RCC), bladder cancer (BC), colorectal cancer with microsatellite instability or
mismatch repair deficiency (MSI-H/dMMR), hepatocellular carcinoma (HCC), classic Hodgkin’s
lymphoma (cHL), melanoma, and head and neck squamous cell carcinoma (HNSCC).
Pembrolizumab has been approved for melanoma, stomach and gastroesophageal cancers,
cervical cancer, BC, HNSCC, NSCLC, cHL, and all advanced solid tumors with MSI-H/dMMR
(Qin et. al., 2019). Avelumab has been approved for Merkel cell carcinoma and BC.
Atezolizumab has been approved for NSCLC and BC. Durvalumab has been approved for BC
and stage III NSCLC (Qin et. al., 2019). Despite the fact that several cancer types are approved
to be treated by these drugs, many of them overlap and there is limited potential for treatment
using this approach for other cancer types not listed. The approval of these drugs by the FDA and
promising results in clinical trials is a step in the right direction when it comes to
PD-1/PD-L1-related immunotherapies, but significant obstacles are still present. The lack of
long-term data, as well as minimal data about the utilization of these drugs in combination with
other cancer therapies, makes it difficult to analyze what the most effective combination of
therapies is for certain cancer types. Another obstacle is the development of immune-related
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adverse events (irAEs). The addition of these immunotherapies to chemotherapy increases the
presence of irAEs significantly. For example, a study showed that 53.6% of patients receiving
atezolizumab in combination with chemotherapy developed irAEs, whereas only 29.1% of
patients receiving chemotherapy alone presented with these adverse events (Qu, et. al., 2021).
The final obstacle that will be touched on, that has minimal studies revolving around it, is the
resistance to PD-1/PD-L1 therapies. The resistance mechanism is particularly tricky and there
has been very limited work done on uncovering the tumor-related antigens associated with
development of this resistance (Qu, et. al., 2021). With more research focused on the
PD-1/PD-L1 therapy resistance mechanism and its associated antigens, the prevalence and
prevention of irAEs, and insight to new combination therapies, the PD-1/PD-L1 pathway will
likely be a frontline target for immunotherapeutic development and usage, and potentially in
more cancer types.
Cytotoxic T-lymphocyte associated antigen (CTLA-4)
Cytotoxic T-lymphocyte associated antigen (CTLA-4) is a CD28 homolog molecule that binds to
a costimulatory molecule, B7, on antigen presenting cells to heighten the activation threshold of
T cells. When CD28 binds B7, this provides a secondary signal to activate the T cell after T-cell
receptor:MHC I/antigen binding, while CTLA-4:B7 binding halts T cell activation
(Rowshanravan et. al., 2018). Inhibition of T cell activation and proliferation leads to a decrease
in the number of T cells capable of their effector functions, which further allows tumor immune
evasion and disease progression. Aside from this function in the tumor microenvironment, it has
also been hypothesized that CTLA-4 produces tonic inhibitory signals in the early stages of
tumorigenesis, increasing T cell activation thresholds and weakening immune responses against
the cancer cells (Intlekofer et. al., 2013). Along with PD-1, CTLA-4 is one of the most

13
TUMOR-INDUCED IMMUNE EVASION OF CD8+ T CELLS
commonly studied immune checkpoints in the tumor microenvironment, as well as one of the
most influential on cancer progression and treatment response. Aside from the cancer
perspective, CTLA-4 is also expressed on regulatory T cells and memory T cells and functions to
prevent autoimmunity by inhibiting activation of self-reactive T cells (Wolchok et. al., 2008).
Relatively early studies of this molecule showed that germline deletion of Ctla4 has been
associated with massive lymphoproliferation and fatal multiorgan tissue destruction (Tevol, et.
al., 1995), while mutations of Ctla4 were associated with immune dysregulation and ultimately
autoimmune disorders (Kuehn, et. al., 2014). CTLA-4 expression is frequently upregulated on
cancer cells as well as tumor infiltrating lymphocytes (TILs) in the tumor microenvironment.
Expression levels are commonly used as an indicator of prognostic capabilities in malignant
disease. In terms of expression, a study revolving around CTLA-4 expression on the dendritic
cells of hepatocellular carcinoma (HCC) patients displayed that CD14+ DCs in these patients
highly expressed CTLA-4. It was found to be crucial for production of molecules that
significantly inhibit T cell function, as well as suppression of antitumor immune responses,
therefore contributing to progression of disease in these patients (Han, et. al., 2013). There are
also several findings showing the difference in expression levels of CTLA-4 between cancer
patients and healthy volunteers. For example, non-small cell lung cancer (NSCLC) patients
demonstrated a much higher proportion of regulatory T cells and significantly increased CTLA-4
expression when compared to healthy volunteers. This study also demonstrated a correlation
between CTLA-4 expression levels and NSCLC disease staging and metastatic progression
(Erfani, et. al., 2012). Due to the fact that Tregs and CTLA-4 are the main inhibitory cells and
molecules of the immune system (Erfani, et. al., 2012), inhibition of CTLA-4 appears to be a
promising area in immunotherapeutic development. There have been numerous preclinical
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studies in murine models that have provided confirmation of CTLA-4-blockade induced
enhancement of antitumor immunity as well as the potential of synergistic effects when used
with other cancer therapies (Peggs, et. al., 2006). In one murine model study, it was hypothesized
that temporary removal of CTLA-4–mediated inhibition may lead to the enhancement of
anti-tumor immunity (Egen, et. al., 2002). Initial experiments in this study used two murine
tumor cell lines, a colon carcinoma and a fibrosarcoma, and administration of antibodies that
would block the interaction of CTLA-4 and B7 resulted in tumor rejection post-implantation.
This phenomenon also came along with the findings of long lasting immunity in the absence of
further treatment. These findings were less prominent in less immunogenic tumors, which
showed a much weaker response to anti-CTLA-4 therapy (Wolchok, et. al., 2008). This study
served as a proof-of-purpose study, and since the publication there has been a wealth of data and
knowledge about this molecule in the context of immunotherapy. Two human monoclonal
anti-CTLA-4 IgG antibodies have been produced using transgenic mouse technologies,
ipilimumab and tremelimumab (Arce Vargas et. al., 2018). They have both been utilized in
several cases of advanced stage cancers. Reports from human trials in melanoma, non-small cell
lung cancer, mesothelioma, prostate, ovarian, breast and urothelial cancer treatment have
displayed a level of efficacy (Arce Vargas et. al., 2018). Alongside the promising data, a variety
of immune related adverse events (irAEs) have been observed in 60-65% of patients. These
frequently impacted the skin, gastrointestinal tract, liver, and endocrine organs. Another
observation has been the presence of autoimmunity in several other organs including the liver,
eyes, nervous system, lungs, heart, kidneys, and joints (Jia et. al., 2020). These antibodies have
also shown correlation with an increase in the diversity of T-cell receptor repertoire
(Rowshanravan et al., 2018), which is consistent with the idea that inhibition of CTLA-4 would
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lead to an increase in T cell activation and proliferation, which would come with an increase in
diversity of T cells that could have the potential to combat cancer cells. Aside from the direct
effects observed, immunological effects such as immune cell infiltration into tumors and tumor
necrosis have also been witnessed. When compared with anti-PD-1 checkpoint blockade therapy,
CTLA-4 comes with increased toxicity, limitations to fewer cancer types, and a lower
recurrence-free survival rate (Liu, et. al., 2020). Another significant obstacle arises when the
necessity for CTLA-4 in prevention of autoimmune disorders is considered. Future directions for
CTLA-4 immunotherapy have been strongly contemplated. Some of these include acquiring
further knowledge on other cancer types that may respond well to this therapy, maneuvering
around the autoimmunity that comes with blockade of CTLA-4, prevention or attenuation of
adverse events, and further studies on the mechanisms of overexpression of CTLA-4 found in the
tumor microenvironment. Acquisition of knowledge in these areas will improve efficacy of drugs
in the development phase, provide further understanding on the therapy and its mechanisms, and
make CTLA-4 blockade a more promising target in the field of immunotherapeutic development.
Conclusion and future directions
Cancer continues to be among the leading causes of death worldwide with new cancers still
being discovered, sometimes more aggressive and less responsive to treatment. Numbers are still
predicted to rise in the coming years, however this increase in occurrence does not necessarily
correlate with an increase in new therapeutic developments. New approaches and technologies in
oncology are essential to combat the rising numbers, and with immuno-oncology on the forefront
of cancer research, emerging immunotherapies are hoped, and expected, to yield promising
clinical benefits as new knowledge is uncovered. To develop new therapies in this field, having a
full understanding of the immune mechanisms that are in favor of or against disease progression
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is crucial. Checkpoint blockade therapies have demonstrated encouraging data, both
pre-clinically and clinically, and advancing this approach by gaining more insight into the
immune-cell makeup and behavior in the tumor microenvironment is a promising future
direction for the field of immuno-oncology. Gaining more understanding about disease responses
and patient outcomes to immunotherapies in order to minimize toxicity and adverse events from
these new therapies is essential to ensure safety of these treatments alongside efficacy. It will
also be crucial to analyze general immune function in these patients during and after these
treatments as long-term effects of immunotherapy on immune function are not well understood.
An important aspect of this will be to study the duration of immunity by monitoring for
recurrence of disease after successful treatment with immunotherapy. Similarly, monitoring for
development of resistance to these therapies is a critical role of immunologists and oncologists as
the utilization of these treatments becomes conventionalized. Immunotherapy provides a strong
sense of optimism for those suffering from cancers that have shown significant responses to
already-developed immunotherapies both clinically and pre-clinically, however there is still an
abundance of work that can be done in terms of targeting other cancer types. As the field
progresses, it will be vital to begin to target the previously mentioned checkpoints, as well as
others, for a wider variety of cancers in order to maximize the number of patients able to benefit
from immunotherapy. These future directions put us in a promising position to yield safe and
efficacious approaches to the development of novel immunotherapeutics.
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